Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TriSalus Life Sciences (TLSI) Shares Outstanding (2021 - 2026)

TriSalus Life Sciences has reported Shares Outstanding over the past 6 years, most recently at $61.4 million for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 90.3% year-over-year to $61.4 million; the TTM value through Mar 2026 reached $61.4 million, up 90.3%, while the annual FY2025 figure was $50.0 million, 59.84% up from the prior year.
  • Shares Outstanding for Q1 2026 was $61.4 million at TriSalus Life Sciences, up from $50.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $61.4 million in Q1 2026 and troughed at $298725.0 in Q1 2022.
  • A 5-year average of $23.7 million and a median of $26.8 million in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: surged 8117.67% in 2023 and later grew 15.78% in 2024.
  • Year by year, Shares Outstanding stood at $347926.0 in 2022, then surged by 7491.62% to $26.4 million in 2023, then rose by 18.42% to $31.3 million in 2024, then soared by 59.84% to $50.0 million in 2025, then increased by 22.83% to $61.4 million in 2026.
  • Business Quant data shows Shares Outstanding for TLSI at $61.4 million in Q1 2026, $50.0 million in Q4 2025, and $49.9 million in Q3 2025.